CRP and cancer: Univariate logistic regression analysis showed that patients with ECOG performance status ≥ 2, Cancer stage III-IV at enrollment, currently undergoing anti-cancer treatment, with accompanying comorbidities, increased WBC, ANC, NLR, LDH, hs-CRP, β2-MG, and D-dimer levels, and decreased eosinophil count and ALB levels were more serious (Table 3).